Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population

Pharmacogenomics

Volumn 13, Issue 7, 2012, Pages 779-787

  Tian, Jun ^a   Qin, Xueying ^a   Fang, Kai ^a   Chen, Qing ^b   Hou, Jing ^c,d   Li, Juan ^e   Yu, Wenzhen ^c,d   Chen, Dafang ^a   Hu, Yonghua ^a,e   Li, Xiaoxin ^c,d  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^d BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^e Beijing Center of Disease Prevention and Control   (China)

Author keywords

Pharmacogenetics

Indexed keywords

BEVACIZUMAB; COMPLEMENT COMPONENT C3; VASCULOTROPIN;

ADULT; AGED; ARMS2 GENE; ARTICLE; C3 GENE; CENTRAL RETINA THICKNESS; CFH GENE; CHINESE; FEMALE; GENE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HTRA1 GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM LESION THICKNESS; MULTICENTER STUDY; PHARMACOGENOMICS; PROSPECTIVE STUDY; RETINA MACULA AGE RELATED DEGENERATION; SERPING1 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VEGF GENE; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS;

ANTIBODIES, MONOCLONAL, HUMANIZED; BIOMARKERS, PHARMACOLOGICAL; CHINA; COMPLEMENT C1 INACTIVATOR PROTEINS; COMPLEMENT FACTOR H; GENETIC ASSOCIATION STUDIES; HUMANS; MACULAR DEGENERATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEINS; SERINE ENDOPEPTIDASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84861109588     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.53     Document Type: Article

References (35)

1. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA 291(15), 1900-1901 (2004). (Pubitemid 38509505)
2. Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration. Am. J. Ophthalmol. 137(3), 486-495 (2004). (Pubitemid 38328641)
3. Wu L, Sun X, Zhou X, Weng C. Causes and 3-year-incidence of blindness in Jing-An District, Shanghai, China 2001-2009. BMC Ophthalmol. 11(1), 10 (2011).
4. Huang S, Zheng Y, Foster PJ, Huang W, He M. Prevalence and causes of visual impairment in Chinese adults in urban southern China. Arch. Ophthalmol. 127(10), 1362-1367 (2009).
5. Chakravarthy U, Evans J, Rosenfeld PJ. Age related macular degeneration. BMJ 340, c981 (2010).
6. Shastry BS. Genetic diversity and medicinal drug response in eye care. Graefes Arch. Clin. Exp. Ophthalmol. 248(8), 1057-1061 (2010).
7. Tufail A, Patel PJ, Egan C et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ 340, c2459 (2010).
8. Fong DS, Custis P, Howes J, Hsu JW. Intravitreal bevacizumab and ranibizumab for age-related macular degeneration: a multicenter, retrospective study. Ophthalmology 117(2), 298-302 (2010).
9. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 364(20), 1897-1908 (2011).
10. Subramanian ML, Ness S, Abedi G et al. Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial. Am. J. Ophthalmol. 148(6), 875-882.e871 (2009).
11. Ng TK, Chen LJ, Liu DT et al. Multiple gene polymorphisms in the complement factor H gene are associated with exudative age-related macular degeneration in Chinese. Invest. Ophthalmol. Vis. Sci. 49(8), 3312-3317 (2008).
12. Dewan A, Liu M, Hartman S et al. HTRA1 promoter polymorphism in wet age-related macular degeneration. Science 314(5801), 989-992 (2006). (Pubitemid 44749943)
13. Yang Z, Tong Z, Chen Y et al. Genetic and functional dissection of HTRA1 and LOC387715 in age-related macular degeneration. PLoS Genet. 6(2), e1000836 (2010).
14. Seddon JM, Francis PJ, George S, Schultz DW, Rosner B, Klein ML. Association of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration. JAMA 297(16), 1793-1800 (2007). (Pubitemid 46658648)
15. Tuo J, Ross RJ, Reed GF et al. The HtrA1 promoter polymorphism, smoking, and age-related macular degeneration in multiple case-control samples. Ophthalmology 115(11), 1891-1898 (2008).
16. Brantley MA Jr, Fang AM, King JM, Tewari A, Kymes SM, Shiels A. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology 114(12), 2168-2173 (2007). (Pubitemid 350181136)
17. Nischler C, Oberkofler H, Ortner C et al. Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration. Acta. Ophthalmol. 89(4), e344-e349 (2011).
18. Orlin A, Hadley D, Chang W et al. Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration. Retina 32(1), 4-9 (2012).
19. Galan A, Ferlin A, Caretti L et al. Association of age-related macular degeneration with polymorphisms in vascular endothelial growth factor and its receptor. Ophthalmology 117(9), 1769-1774 (2010).
20. Lin JM, Wan L, Tsai YY et al. Vascular endothelial growth factor gene polymorphisms in age-related macular degeneration. Am. J. Ophthalmol. 145(6), 1045-1051 (2008).
21. Ennis S, Jomary C, Mullins R et al. Association between the SERPING1 gene and age-related macular degeneration: a two-stage case-control study. Lancet 372(9652), 1828-1834 (2008).
22. Lee AY, Kulkarni M, Fang AM, Edelstein S, Osborn MP, Brantley MA. The effect of genetic variants in SERPING1 on the risk of neovascular age-related macular degeneration. Br. J. Ophthalmol. 94(7), 915-917 (2010).
23. Yates JR, Sepp T, Matharu BK et al. Complement C3 variant and the risk of age-related macular degeneration. N. Engl. J. Med. 357(6), 553-561 (2007). (Pubitemid 47236280)
24. Despriet DD, Van Duijn CM, Oostra BA et al. Complement component C3 and risk of age-related macular degeneration. Ophthalmology 116(3), 474-480.e2 (2009).
25. Kim NR, Kang JH, Kwon OW, Lee SJ, Oh JH, Chin HS. Association between complement factor H gene polymorphisms and neovascular age-related macular degeneration in Koreans. Invest. Ophthalmol. Vis. Sci. 49(5), 2071-2076 (2008).
26. Mori K, Gehlbach PL, Kabasawa S et al. Coding and noncoding variants in the CFH gene and cigarette smoking influence the risk of age-related macular degeneration in a Japanese population. Invest. Ophthalmol. Vis. Sci. 48(11), 5315-5319 (2007). (Pubitemid 351260946)
27. Mckibbin M, Ali M, Bansal S et al. CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration. Br. J. Ophthalmol. 96(2), 208-212 (2012).
28. Kloeckener-Gruissem B, Barthelmes D, Labs S et al. Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD. Invest. Ophthalmol. Vis. Sci. 52(7), 4694-4702 (2011).
29. Lu F, Hu J, Zhao P et al. HTRA1 variant increases risk to neovascular age-related macular degeneration in Chinese population. Vision Res. 47(24), 3120-3123 (2007). (Pubitemid 47615119)
30. Qu Y, Dai H, Zhou F et al. Vascular endothelial growth factor gene polymorphisms and risk of neovascular age-related macular degeneration in a Chinese cohort. Ophthalmic Res. 45(3), 142-148 (2011).
31. Nakata I, Yamashiro K, Yamada R et al. Association between the SERPING1 gene and age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese. PLoS ONE 6(4), e19108 (2011).
32. Cui L, Zhou H, Yu J et al. Noncoding variant in the complement factor H gene and risk of exudative age-related macular degeneration in a Chinese population. Invest. Ophthalmol. Vis. Sci. 51(2), 1116-1120 (2010).
33. Francis PJ. The influence of genetics on response to treatment with ranibizumab (Lucentis) for age-related macular degeneration: the Lucentis Genotype Study. Trans. Am. Ophthalmol. Soc. 109, 115-156 (2011).
34. Subramanian ML, Ness S, Abedi G et al. Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial. Am. J. Ophthalmol. 148(6), 875-882.e1 (2009).
35. Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, Noureddin BN. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am. J. Ophthalmol. 145(2), 249-256 (2008).